arrow
L

Lisa Mayr

Medical University of Vienna
H指数:19
被引数:4,194

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nanopore-based liquid biopsy analysis enables preoperative tumor classification in pediatric brain tumors

基于纳米孔的液体活检分析能够实现儿童脑肿瘤的术前肿瘤分类

2026-08-010
OA
Assessment of treatment response in recurrent medulloblastoma using craniospinal MRI

评估复发性髓母细胞瘤对治疗的反应:使用颅脑脊髓MRI

2026-07-010
PRE
Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma

联合靶向CDK4/6和MEK逆转治疗耐药型BRAF突变型儿童高级别胶质瘤的间充质转化

2026-05-160
OAAI
Impact of Bevacizumab treatment intervals on surgical interventions in pediatric neuro-oncology

贝伐珠单抗治疗间隔对儿科神经肿瘤学中手术干预的影响

2026-01-010
PRE
Combinatorial targeting of avapritinib-driven MAPK activation in pediatric high-grade glioma

阿伐普利尼布诱导的MAPK激活在儿童高级别胶质瘤中的组合靶向治疗

2025-11-010
OAAI
DIFFUSE MIDLINE GLIOMA, H3 K27 AND BRAF/FGFR1 CO-ALTERED: DISTINCT BIOLOGY AND THERAPEUTIC OPPORTUNITIES

弥漫性中线胶质瘤,H3 K27和BRAF/FGFR1共突变:独特的生物学特征和治疗机遇

2025-10-010
OAAI
Cellular hierarchies of embryonal tumors with multilayered rosettes are shaped by oncogenic microRNAs and receptor-ligand interactions

胚胎性多层层状-rosettes肿瘤的细胞层次结构由致癌microRNAs和受体-配体相互作用塑造。

2025-05-260
OA
Detection of H3F3A K27M or BRAF V600E in liquid biopsies of brain tumor patients as diagnostic and monitoring biomarker: impact of tumor localization and sampling method

脑肿瘤患者液体活检中H3F3A K27M或BRAF V600E的检测作为诊断和监测生物标志物:肿瘤定位和采样方法的影响

2025-01-030
OA
Real-World Performance of Integrative Clinical Genomics in Pediatric Precision Oncology

综合临床基因组学在儿科精准肿瘤学中的真实表现

2024-12-010
OAAI
Alternative lengthening of telomere-based immortalization renders H3G34R-mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens
2024-11-180
PRE
A NEW SUBTYPE OF DIFFUSE MIDLINE GLIOMA, H3 K27 AND BRAF/FGFR1 CO-ALTERED, EXHIBITS SPECIFIC BIOLOGICAL CHARACTERISTICS AND NEW THERAPEUTIC VULNERABILITIES
2024-11-110
PRE
Feasibility, tolerability, and first experience of intracystic treatment with peginterferon alfa-2a in patients with cystic craniopharyngioma
2024-07-101
OAAI
FEASIBILITY, TOLERABILITY AND FIRST EXPERIENCE OF INTRACYSTIC TREATMENT WITH PEGINTERFERON ALFA-2A IN PATIENTS WITH CYSTIC CRANIOPHARYNGIOMA
2024-06-180
OAAI
PRE-OPERATIVE TUMOUR CLASSIFICATION USING NANOPORE SEQUENCING OF CEREBROSPINAL FLUID
2024-06-180
OAAI